The U.S. Food and Drug Administration on Friday approved Amgen Inc’s biosimilar copy of Johnson & Johnson’s blockbuster rheumatoid arthritis drug, Remicade, according to the regulator’s website. The biosimilar, Avsola, has the same chemical components, dosage form and strength as Remicade and would treat a range of autoimmune disorders. Amgen did not give the pricing of the drug immediately, but said is confident to compete in the biosimilar market. …read more
Source:: Yahoo Finance
